By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Oragenics, Inc. 

12085 Research Drive

Alachua  Florida  32615  U.S.A.
Phone: 386-418-4018 Fax: 386-462-0875




Company News
Oragenics (OGEN) Doses First Patient In Phase II Clinical Trial Of AG013 For Oral Mucositis 8/31/2017 8:04:05 AM
Oragenics (OGEN) Announces Completion Of Second Closing Of $3.0 Million Preferred Stock Private Placement 7/26/2017 6:43:13 AM
Oragenics (OGEN) Announces Notification Of Noncompliance With Additional NYSE MKT Continued Listing Standard 6/12/2017 8:40:24 AM
Oragenics (OGEN) Presents Development Of Novel Lantibiotic Against Clostridium Difficile At The ICAAC Conference 6/7/2017 8:47:16 AM
Oragenics (OGEN) Announces $3.0 Million Preferred Stock Private Placement And $2.4 Million Loan 5/11/2017 6:16:48 AM
Oragenics (OGEN) Provides First Quarter 2017 Update 4/18/2017 11:27:37 AM
Oragenics (OGEN) Receives Audit Opinion With Going Concern Explanation 3/6/2017 6:54:40 AM
Oragenics (OGEN) Shareholder Update 1/4/2017 9:36:04 AM
Oragenics (OGEN) Presents Engineering Of Improved Lantibiotic Variants At American Society for Microbiology Conference On Antibacterial Development 12/15/2016 11:58:09 AM
U.S. FDA Grants Fast Track Designation For The Development Of Oragenics (OGEN)’ AG013 For Oral Mucositis 11/21/2016 11:54:55 AM